NASDAQ:KOOL - Cesca Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.2979 -0.01 (-3.25 %) (As of 12/16/2018 12:09 PM ET)Previous Close$0.2979Today's Range$0.2905 - $0.311452-Week Range$0.22 - $3.92Volume198,209 shsAverage Volume657,150 shsMarket Capitalization$6.45 millionP/E RatioN/ADividend YieldN/ABeta-0.57 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited. Receive KOOL News and Ratings via Email Sign-up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Laboratory apparatus & furniture Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KOOL Previous Symbol CUSIPN/A Webwww.cescatherapeutics.com Phone916-858-5100 Debt Debt-to-Equity Ratio0.06 Current Ratio1.68 Quick Ratio0.87 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.52 million Price / Sales0.44 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book0.10 Profitability EPS (Most Recent Fiscal Year)($0.98) Net IncomeN/A Net Margins-323.73% Return on Equity-22.66% Return on Assets-13.52% Miscellaneous Employees70 Outstanding Shares21,650,000Market Cap$6.45 million OptionableNot Optionable Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions What is Cesca Therapeutics' stock symbol? Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL." How were Cesca Therapeutics' earnings last quarter? Cesca Therapeutics Inc (NASDAQ:KOOL) announced its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.02. The biotechnology company had revenue of $3.11 million for the quarter, compared to analysts' expectations of $2.97 million. Cesca Therapeutics had a negative net margin of 323.73% and a negative return on equity of 22.66%. View Cesca Therapeutics' Earnings History. When is Cesca Therapeutics' next earnings date? Cesca Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for Cesca Therapeutics. What price target have analysts set for KOOL? 1 Wall Street analysts have issued 1-year price objectives for Cesca Therapeutics' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Cesca Therapeutics' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 571.4% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics. What is the consensus analysts' recommendation for Cesca Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics. Has Cesca Therapeutics been receiving favorable news coverage? News articles about KOOL stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cesca Therapeutics earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are some of Cesca Therapeutics' key competitors? Some companies that are related to Cesca Therapeutics include IMMURON LTD/S (IMRN), Agile Therapeutics (AGRX), Millendo Therapeutics (MLND), Vical (VICL), Adial Pharmaceuticals (ADIL), OvaScience (OVAS), Q BioMed (QBIO), Xenetic Biosciences (XBIO), Aethlon Medical (AEMD), SCYNEXIS (SCYX), Biomerica (BMRA), Provectus Biopharmaceuticals (PVCT), Eyegate Pharmaceuticals (EYEG), Ceapro (CRPOF) and Zivo Bioscience (ZIVO). Who are Cesca Therapeutics' key executives? Cesca Therapeutics' management team includes the folowing people: Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 45)Mr. James Xu, Director, Gen. Counsel & Sr. VP of Legal Affairs (Age 47)Dr. Xiaochun Xu Ph.D., Chairman & CEO (Age 47)Mr. Philip H. Coelho, Chief Technology Officer (Age 74)Ms. Haihong Zhu, Pres of ThermoGenesis Who are Cesca Therapeutics' major shareholders? Cesca Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (0.44%). Company insiders that own Cesca Therapeutics stock include (Hong Kong) Ltd Boyalife and Thomis Joseph. View Institutional Ownership Trends for Cesca Therapeutics. Which major investors are selling Cesca Therapeutics stock? KOOL stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. View Insider Buying and Selling for Cesca Therapeutics. How do I buy shares of Cesca Therapeutics? Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cesca Therapeutics' stock price today? One share of KOOL stock can currently be purchased for approximately $0.2979. How big of a company is Cesca Therapeutics? Cesca Therapeutics has a market capitalization of $6.45 million and generates $14.52 million in revenue each year. Cesca Therapeutics employs 70 workers across the globe. What is Cesca Therapeutics' official website? The official website for Cesca Therapeutics is http://www.cescatherapeutics.com. How can I contact Cesca Therapeutics? Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected] MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 166 (Vote Outperform)Underperform Votes: 189 (Vote Underperform)Total Votes: 355MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?